MENU
PBE
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

PBE stock forecast, quote, news & analysis

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index... Show more

Category: #Health
PBE
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for PBE with price predictions
Jun 22, 2026

Aroon Indicator for PBE shows an upward move is likely

PBE's Aroon Indicator triggered a bullish signal on June 22, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 234 similar instances where the Aroon Indicator showed a similar pattern. In of the 234 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 28, 2026. You may want to consider a long position or call options on PBE as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PBE just turned positive on June 09, 2026. Looking at past instances where PBE's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Market Cap

The average market capitalization across the Invesco Biotechnology & Genome ETF ETF is 23.39B. The market cap for tickers in the group ranges from 437.3M to 187.28B. AMGN holds the highest valuation in this group at 187.28B. The lowest valued company is MYGN at 437.3M.

High and low price notable news

The average weekly price growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 15%. For the same ETF, the average monthly price growth was 39%, and the average quarterly price growth was 74%. XNCR experienced the highest price growth at 15%, while ILMN experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 11%. For the same stocks of the ETF, the average monthly volume growth was 45% and the average quarterly volume growth was 308%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 50
Price Growth Rating: 45
SMR Rating: 66
Profit Risk Rating: 67
Seasonality Score: 33 (-100 ... +100)
View a ticker or compare two or three
PBE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Powershares Exchange Traded Fund Trust227 E Prairie AveWheaton
Phone
N/A
Web
www.invescopowershares.com
Aroon Indicator for PBE shows an upward move is likely